Ipamorelin in Canada: Research Guide (2026)

For laboratory research use only. Nothing on this page is medical advice, and no compound discussed here is offered for human use. Ipamorelin has never been an authorised drug in Canada or anywhere else.

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue — a selective agonist of the ghrelin receptor (GHS-R1a). It was developed in the 1990s in pharmaceutical research (the defining characterisation is Raun et al., European Journal of Endocrinology, 1998) and became notable for one property above all: selectivity. In the animal pharmacology, ipamorelin stimulated growth-hormone release without the meaningful ACTH, cortisol or prolactin elevation seen with earlier secretagogues in the same class — which is why it remains the reference “clean” GH secretagogue in research designs.

That selectivity also explains where it sits in the research landscape: it is the ghrelin-receptor half of the GH-axis toolkit, studied alongside — and against — the GHRH analogs (sermorelin, CJC-1295, tesamorelin), which act on a completely different receptor. It entered clinical development decades ago but was never brought to approval anywhere, and in Canada it exists only as a research chemical.

The research record

Ipamorelin’s literature has three layers. The original pharmacology: receptor-selectivity and GH-release characterisation in animal models, the work that defined the compound. The clinical-development history: it was investigated in early human trials (including for post-operative gastrointestinal motility) before development was discontinued — those trials belong to that programme and its formulation, not to research material, and no equivalence is implied. And the comparative GH-axis literature, where ipamorelin serves as the selective ghrelin-receptor reference point against GHRH-pathway compounds. As with every compound on this site, these are descriptions of what was measured in studies, not claims about research vials.

Ipamorelin vs CJC-1295, sermorelin and tesamorelin

The GH-axis compounds split into two receptor classes that are not interchangeable in research designs. Ipamorelin acts at the ghrelin receptor (GHS-R1a). Sermorelin, CJC-1295 and tesamorelin are GHRH analogs acting at the pituitary GHRH receptor. Because the two pathways are distinct, paired designs appear throughout the literature — which is why Quantum also stocks the combined CJC-1295 + Ipamorelin (CP10) blend. The full mechanistic comparison lives in our dedicated guide: Sermorelin vs Ipamorelin vs Tesamorelin, and the GHRH side’s deepest-studied compound has its own page at Tesamorelin in Canada.

Regulatory status in Canada

Ipamorelin has never been an authorised drug in Canada — a search of Health Canada’s Drug Product Database returns no product containing it (verified October 2026) — nor is it approved anywhere else; its clinical development was discontinued without approval. In Canada it may be sold only as a research-use-only laboratory chemical. The wider framework: peptide legality in Canada.

Purity and the COA question

For a research chemical, the meaningful quality question is what is actually in the vial. Quantum’s per-batch program applies to ipamorelin as to every compound: independent third-party HPLC purity (≥99% target) and mass-spec identity confirmation, with the batch number printed on the vial and the certificate published on the lab results hub as testing completes. The COA hub explains how to read one.

Where to buy ipamorelin in Canada

Quantum Peptides supplies ipamorelin as a standalone 5mg lyophilized research vial — see the Ipamorelin 5mg product page — and as half of the CP10 CJC-1295 + Ipamorelin blend, shipping domestically from Edmonton. The supplied format is dry lyophilized peptide that a laboratory reconstitutes for its own protocols. For research use only — not for human consumption. New to sourcing? Start with how to buy research peptides in Canada and how to verify a legit supplier.

Frequently asked questions

Is ipamorelin available in Canada?

Only as a research-use-only laboratory chemical. It has never been an authorised drug in Canada or any other country — Health Canada’s Drug Product Database returns no match (verified October 2026).

Do you need a prescription for ipamorelin in Canada?

There is no prescription to require: no ipamorelin drug product exists to prescribe. Research-labelled ipamorelin is a laboratory material sold for research use only and is not for human use.

Why is ipamorelin called a “selective” secretagogue?

In the defining animal pharmacology, ipamorelin stimulated growth-hormone release without the meaningful ACTH, cortisol or prolactin elevation produced by earlier compounds in its class. That receptor selectivity is a description of study findings, not an outcome claim about research material.

What is the difference between ipamorelin and CJC-1295?

Different receptors entirely: ipamorelin is a ghrelin-receptor (GHS-R1a) agonist, while CJC-1295 is a GHRH analog acting at the pituitary GHRH receptor. The two pathways are why the compounds appear together in the CP10 blend and throughout paired research designs.

What is the ipamorelin dosage?

We don’t provide protocols: this material is sold for laboratory research only, and figures in the literature belong to specific studies and the discontinued clinical programme, not to research vials.

Does Quantum’s ipamorelin come with a COA?

Every batch goes through independent third-party HPLC and mass-spectrometry testing; the batch-specific certificate is published on the lab results hub as testing completes. Check the current batch certificate there before purchase.

For laboratory research use only. Not for human consumption. Not evaluated for approval by Health Canada. This page summarises regulatory records and published research for educational purposes and is not medical advice.